

- **Name:** IZZATI BINTI WAN MAHARUDDIN
- **Current Position & Affiliation:** Clinical Oncologist
Sarawak General Hospital, Kuching, Sarawak
- **Country:** Malaysia

• **Biography:**

Dr Izzati is a clinical oncologist from Sarawak General Hospital. She graduated in Masters of Clinical Oncology from the University of Malaya. Her special interest is in womens' health and the treatment of gynecological malignancies, head and neck cancers, and cancers of the hepatobiliary system. Along with her colleague, she is developing cervical cancer care in Sarawak and is now leading the brachytherapy unit for cervical cancer in Sarawak General Hospital.

• **Educational Background:**

- 2012** Medical Degree (MD), University of North Sumatera, Indonesia
- 2022** Masters of Clinical Oncology (MCO), University of Malaya, Malaysia

• **Professional Experience:**

Administrative Course Director

- Duties
- ASCO-Sarawak Multidisciplinary Management Course on Cervical Cancer 2024, Sarawak General Hospital, 1 Aug 2024 – 3 Aug 2024

Committee Member

- FARO Education and Training Committee representative of MOS 2024

Clinical Principal Investigator

Research

- A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC), 2024, AstraZeneca
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato- DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast (Tropion_Breast04), 2024, AstraZeneca

Sub-investigator

- Identifying the relationship of human papillomavirus oncotypes and cervical cancer in Sarawakian patients via whole genome assembly, 2024, Ministry of Higher Education Malaysia
- CT based contouring in the IMRT Era for Curative treatment of Nasopharyngeal Carcinoma: A Sarawak Experience, 2024, Sarawak General

Hospital

- Blood-based Epigenetic Profiling of Colorectal Cancer Patients In East Malaysia, Sub- Investigator, 2024, MiRXES Lab Pte. Ltd
- Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN Ovarian Cancer Project protocol, 2023, National Cancer Hospital Japan
- A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ±Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3), 2023, AstraZeneca
- A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer (EPIK-O), 2022, Novartis
- Hyperthermia in Treating Patients with Painful Unresectable Abdominal or Pelvic Malignancy, 2021, Adipolabs
- Immune modulatory effect of hyperthermia during treatment of recurrent or metastatic solid organ malignancies, 2021, Adipolabs,
- Experience sharing of developing cervical cancer care at Sarawak General Hospital, ATLAS monthly webinar on cervical cancer, 2025
- Cervical Cancer Management, Implication, and Impact, Cervical Cancer Awareness and Colposcopy Workshop, Sarawak, 2024
- Skin Cancer Chemoradiotherapy: Rationale and Clinical Applications, Borneo Plastic Surgery Symposium, Sarawak, 2023
- CT in Oncology Imaging: From Diagnosis to Treatment, CT Vital Role in Oncology, Sarawak, 2023
- Benefits of hyperthermia as an adjunctive treatment for oncology, International Virus Research Alliance Seminar (IVRA 2022), Seoul, 2022
- Abstract: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211), Best of ASCO Malaysia Virtual Platform, 2022

Speaker

• Professional Organizations:

Malaysian Oncological Society

Member

2023 – current

European Society of Medical Oncology

Member

2019 – current

Society for Cancer Advocacy and Awareness Kuching,
Sarawak

Member and Medical Advisor

2024 – current

• Main Scientific Publications:

Thesis

The Outcome of Pre-Operative Chemotherapy for Osteosarcoma With or Without High Dose Methotrexate in University Malaya Medical Centre, 2022

Case Report

Spontaneous Remission of Acute Myeloid Leukemia (AML), 2018

